Female nonsmokers exposed to passive smoking >30 years have increased risk of lung cancer
the ONA take:
According to a new study published in the journal Annals of Oncology, researchers from Stanford University School of Medicine in Stanford, California, have found that women who are exposed to smoking in the home for greater than 30 years have an increased risk for developing lung cancer despite having never smoked compared with women who were not exposed to passive smoking.
For the study, researchers identified 76,304 women between the ages 50 and 79 years. Of those, 6.2% were current smokers, 41.68% were former smokers, 47.36% were nonsmokers but exposed to passive smoking, and 4.77% were never smokers and had no exposure to passive smoking. The women were followed for an average of 10.5 years.
During that time, 901 women developed lung cancer. Results showed that current smokers were 13.44 times more likely to develop lung cancer compared with never-smokers, and former smokers were 4.2 times more likely than never-smokers.
There was no statistically significant difference of risk between non-smokers with passive smoking exposure and those without passive smoking exposure. When researchers conducted subgroup analyses, there was a borderline significant risk of lung cancer among nonsmokers exposed to passive smoking for more than 30 years versus women with no home exposure (HR = 1.61).
Women who are exposed to smoking in the home for greater than 30 years have an increased risk.
The analysis also found that women who smoke are 13 times more likely to develop lung cancer than those who have never smoked, but quitting significantly reduces this risk. The study, published in Annals of Oncology, used data from the Women's Health Initiative Observational Study cohort to investigate the relationship between active and passive smoking and lung cancer incidence in women.
Sign Up for Free e-newsletters
- Risk Factors for Arterial, Venous Thrombosis Differ in Polycythemia Vera
- Patient Satisfaction Ratings Can Be Negatively Impacted by Nurse Staffing Ratio
- Dietary Estrogens Reduced Efficacy of Novel Breast Cancer Therapy
- FDA Issues Warning for Rolapitant Injectable Emulsion in the Treatment of CINV
- BRCA Mutation Improves Prognosis for 2-year Survival in Younger-onset TNBC
- Pertuzumab Regimen Approved for Adjuvant, Neoadjuvant Therapy in Specific Breast Cancers
- Common Oncologic Emergencies That Occur With Multiple Myeloma
- Artificial Sweeteners and Cancer Risk (Fact Sheet)
- Blueberry Extract May Boost Efficacy of Radiotherapy for Cervical Cancer
- Breast Implants Associated With Increased Risk of Breast Anaplastic Large-cell Lymphoma
- Survival Outcomes in Relapsed Hepatocellular Carcinoma Improved With Cabozantinib
- OS Similar With Gemcitabine Plus S-1 vs Standard Therapy for Biliary Tract Cancer
- Feasibility and Outcomes of Modified Enhanced Recovery After Surgery for Nursing Management of Aged Patients Undergoing Esophagectomy
- Urine Drug Testing Policy Can Assist Opioid Treatment Decisions
- Resolving Vaginal Dryness in Women With a History of Breast Cancer
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|